Huan-Huan Tang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Huan-Huan Tang has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Gang Chen
Department of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, People’s Republic of China
2 shared publications - Beibei Huang
Research Department, Affiliated Cancer Hospital, Guangxi Medical University, 530021 Nanning, Guangxi, China
1 shared publication - Hongbo Mo
Department of Pathology, First Affiliated Hospital of Guangxi Medical University, 530021 Nanning, Guangxi, China
1 shared publication - Hongquan Liu
Department of Pathology, First Affiliated Hospital of Guangxi Medical University, 530021 Nanning, Guangxi, China
1 shared publication - Jian-Jun Li
Department of General Surgery, The Second Affiliated Hospital of Guangxi Medical University, Nanning, P.R. China
1 shared publication - Ke-Jun Wu
Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, P.R. China
1 shared publication
Latest Publications
- Open Access
- 22 August 2026
- Published by Springer Nature in Hereditas
- Vol. 163 (1)
Multi-omics analysis reveals ANAPC1 overexpression and a potential TEAD4-associated regulatory relationship in cholangiocarcinoma
Background: Cholangiocarcinoma (CHOL) is a highly heterogeneous and aggressive malignancy that is frequently diagnosed at an advanced stage because of the lack of early biomarkers, resulting in a poor prognosis. Although ANAPC1 overexpression has been reported in other cancers, its role and regulatory mechanisms in CHOL remain insufficiently characterized. Objectives: To characterize ANAPC1 expression in CHOL, identify candidate upstream transcriptional regulators, and elucidate the associated functional programs and pathways. Methods: Multi-omics profiling was integrated with in-house immunohistochemical validation. Differential expression analyses, CRISPR-based functional screening, transcription-factor prioritization, ChIP-seq with epigenomic annotation, gene set enrichment analysis, spatial transcriptomics, and single-cell RNA-seq were conducted to investigate ANAPC1-associated regulatory mechanisms in CHOL.Structural modeling of predicted TEAD4–DNA complexes was additionally performed to assess the structural compatibility between TEAD4 and candidate ANAPC1 promoter motifs. Results: ANAPC1 was significantly overexpressed in CHOL at both the transcriptomic level (436 CHOL vs. 213 non-CHOL samples) and the protein level (66 CHOL vs. 99 non-CHOL tissues), with spatial enrichment in cholangiocytes. Public CRISPR dependency screening indicated that ANAPC1 loss was associated with reduced cellular fitness in several CHOL cell lines, including HUCCT1. Integrative analyses identified TEAD4 as a candidate upstream regulator of ANAPC1, and TEAD4 was upregulated in CHOL. Public ChIP-seq and epigenomic datasets across multiple cell lines, including HUCCT1, HepG2, BE2-C, and MDA-MB-231, suggested TEAD4 occupancy at the ANAPC1 locus, together with active chromatin features such as H3K27ac signals near the promoter region. Across several bulk transcriptomic datasets, TEAD4 and ANAPC1 showed positive expression associations of varying magnitude, whereas spatial transcriptomics indicated partially overlapping regional enrichment within malignant areas.Protein–DNA complex modeling of a predicted candidate TEAD4–ANAPC1 promoter DNA complex yielded an ipTM score of 0.71 and a pTM score of 0.62 for the top-ranked candidate promoter motif. GSEA identified positive enrichment of proliferation- and RNA-processing-related pathways and negative enrichment of several immune-related pathways within the ANAPC1-correlated transcriptomic profile. Single-cell analysis further localized ANAPC1 expression mainly to cholangiocytes and identified a statistically significant but extremely weak cell-level correlation with TEAD4. Conclusions: These findings support the hypothesis of a putative TEAD4–ANAPC1 regulatory relationship in CHOL based on integrative epigenomic, transcriptomic, spatial, and structural analyses. Direct experimental validation is required to determine whether TEAD4 functionally regulates ANAPC1 transcription in cholangiocarcinoma.
- 22 August 2026
- Published by Springer Nature in Hereditas
- Vol. 163 (1)
Open AccessMulti-omics analysis reveals ANAPC1 overexpression and a potential TEAD4-associated regulatory relationship in cholangiocarcinoma
Background: Cholangiocarcinoma (CHOL) is a highly heterogeneous and aggressive malignancy that is frequently diagnosed at an advanced stage because of the lack of early biomarkers, resulting in a poor prognosis. Although ANAPC1 overexpression has been reported in other cancers, its role and regulatory mechanisms in CHOL remain insufficiently characterized. Objectives: To characterize ANAPC1 expression in CHOL, identify candidate upstream transcriptional regulators, and elucidate the associated functional programs and pathways. Methods: Multi-omics profiling was integrated with in-house immunohistochemical validation. Differential expression analyses, CRISPR-based functional screening, transcription-factor prioritization, ChIP-seq with epigenomic annotation, gene set enrichment analysis, spatial transcriptomics, and single-cell RNA-seq were conducted to investigate ANAPC1-associated regulatory mechanisms in CHOL.Structural modeling of predicted TEAD4–DNA complexes was additionally performed to assess the structural compatibility between TEAD4 and candidate ANAPC1 promoter motifs. Results: ANAPC1 was significantly overexpressed in CHOL at both the transcriptomic level (436 CHOL vs. 213 non-CHOL samples) and the protein level (66 CHOL vs. 99 non-CHOL tissues), with spatial enrichment in cholangiocytes. Public CRISPR dependency screening indicated that ANAPC1 loss was associated with reduced cellular fitness in several CHOL cell lines, including HUCCT1. Integrative analyses identified TEAD4 as a candidate upstream regulator of ANAPC1, and TEAD4 was upregulated in CHOL. Public ChIP-seq and epigenomic datasets across multiple cell lines, including HUCCT1, HepG2, BE2-C, and MDA-MB-231, suggested TEAD4 occupancy at the ANAPC1 locus, together with active chromatin features such as H3K27ac signals near the promoter region. Across several bulk transcriptomic datasets, TEAD4 and ANAPC1 showed positive expression associations of varying magnitude, whereas spatial transcriptomics indicated partially overlapping regional enrichment within malignant areas.Protein–DNA complex modeling of a predicted candidate TEAD4–ANAPC1 promoter DNA complex yielded an ipTM score of 0.71 and a pTM score of 0.62 for the top-ranked candidate promoter motif. GSEA identified positive enrichment of proliferation- and RNA-processing-related pathways and negative enrichment of several immune-related pathways within the ANAPC1-correlated transcriptomic profile. Single-cell analysis further localized ANAPC1 expression mainly to cholangiocytes and identified a statistically significant but extremely weak cell-level correlation with TEAD4. Conclusions: These findings support the hypothesis of a putative TEAD4–ANAPC1 regulatory relationship in CHOL based on integrative epigenomic, transcriptomic, spatial, and structural analyses. Direct experimental validation is required to determine whether TEAD4 functionally regulates ANAPC1 transcription in cholangiocarcinoma.
- Open Access
- 18 August 2026
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 31 (8)
Multimodal Analysis Reveals Aberrant Expression of SUMO2 and Its Significant Association With Key Mechanisms of Metabolic Pathways in Hepatocellular Carcinoma
Background:Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide. However, the role of small ubiquitin-like modifier 2 (SUMO2), a core member of the small ubiquitin-like modifier (SUMO) family, regarding its expression patterns and metabolism-related functions in HCC remains inadequately understood.Methods:A multidimensional analytical framework was applied, integrating immunohistochemistry (153 HCC vs. 21 non-HCC samples), proteomics (159 paired samples), bulk transcriptomics (3240 HCC vs. 2267 non-HCC samples), single-cell RNA sequencing (RNA-seq) (10 HCC vs. 8 non-HCC samples), spatial transcriptomics, and external CRISPR/Cas9 functional genomics data. Systematic analyses included standardized mean difference (SMD), pathway enrichment, pseudotime trajectory inference, in silico knockout, cell–cell communication, metabolic flux scoring, immune infiltration, clinical correlation, drug sensitivity prediction, and molecular docking.Results:At the protein level, immunohistochemistry (nuclear positivity) and external proteomic data collectively demonstrated consistent SUMO2 overexpression in HCC. Consistent upregulation was also observed at the mRNA level across large-scale cohorts. Single-cell RNA-seq and spatial transcriptomics localized SUMO2 enrichment to malignant hepatocytes and tumor-dominant regions. CRISPR-mediated SUMO2 knockout suppressed proliferation in multiple HCC cell lines. Mechanistically, high SUMO2 expression was significantly associated with metabolic reprogramming involving glycolysis/gluconeogenesis, pyruvate metabolism, and the tricarboxylic acid cycle. SUMO2-high malignant hepatocyte subpopulations exhibited enhanced activity of the macrophage migration inhibitory factor signaling axis and enhanced iron-sensor interactions. Further, the immune infiltration analysis revealed a negative correlation between SUMO2 expression and M1 macrophages and a positive correlation between follicular helper T cells and regulatory T cells. Clinically, elevated SUMO2 levels were found to be associated with adverse prognostic features. Furthermore, high SUMO2 expression was associated with increased sensitivity to dasatinib, and molecular docking simulations predicted potential binding between SUMO2 and dasatinib, with a Vina score of −8.5 kcal/mol.Conclusions:SUMO2 is aberrantly expressed at the protein, mRNA, single-cell, and spatial transcriptomic levels in HCC and is significantly associated with metabolic reprogramming and altered migration inhibitory factor (MIF)-mediated intercellular communication, suggesting its potential as a novel biomarker for diagnosis and treatment.
- 18 August 2026
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 31 (8)
Open AccessMultimodal Analysis Reveals Aberrant Expression of SUMO2 and Its Significant Association With Key Mechanisms of Metabolic Pathways in Hepatocellular Carcinoma
Background:Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide. However, the role of small ubiquitin-like modifier 2 (SUMO2), a core member of the small ubiquitin-like modifier (SUMO) family, regarding its expression patterns and metabolism-related functions in HCC remains inadequately understood.Methods:A multidimensional analytical framework was applied, integrating immunohistochemistry (153 HCC vs. 21 non-HCC samples), proteomics (159 paired samples), bulk transcriptomics (3240 HCC vs. 2267 non-HCC samples), single-cell RNA sequencing (RNA-seq) (10 HCC vs. 8 non-HCC samples), spatial transcriptomics, and external CRISPR/Cas9 functional genomics data. Systematic analyses included standardized mean difference (SMD), pathway enrichment, pseudotime trajectory inference, in silico knockout, cell–cell communication, metabolic flux scoring, immune infiltration, clinical correlation, drug sensitivity prediction, and molecular docking.Results:At the protein level, immunohistochemistry (nuclear positivity) and external proteomic data collectively demonstrated consistent SUMO2 overexpression in HCC. Consistent upregulation was also observed at the mRNA level across large-scale cohorts. Single-cell RNA-seq and spatial transcriptomics localized SUMO2 enrichment to malignant hepatocytes and tumor-dominant regions. CRISPR-mediated SUMO2 knockout suppressed proliferation in multiple HCC cell lines. Mechanistically, high SUMO2 expression was significantly associated with metabolic reprogramming involving glycolysis/gluconeogenesis, pyruvate metabolism, and the tricarboxylic acid cycle. SUMO2-high malignant hepatocyte subpopulations exhibited enhanced activity of the macrophage migration inhibitory factor signaling axis and enhanced iron-sensor interactions. Further, the immune infiltration analysis revealed a negative correlation between SUMO2 expression and M1 macrophages and a positive correlation between follicular helper T cells and regulatory T cells. Clinically, elevated SUMO2 levels were found to be associated with adverse prognostic features. Furthermore, high SUMO2 expression was associated with increased sensitivity to dasatinib, and molecular docking simulations predicted potential binding between SUMO2 and dasatinib, with a Vina score of −8.5 kcal/mol.Conclusions:SUMO2 is aberrantly expressed at the protein, mRNA, single-cell, and spatial transcriptomic levels in HCC and is significantly associated with metabolic reprogramming and altered migration inhibitory factor (MIF)-mediated intercellular communication, suggesting its potential as a novel biomarker for diagnosis and treatment.